Description:
This inhaler contains a combination of Formoterol (6 mcg), a long-acting bronchodilator, and Fluticasone Propionate (250 mcg), an inhaled corticosteroid. It is used for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). The formulation helps to control symptoms such as wheezing, breathlessness, chest tightness, and coughing by reducing airway inflammation and keeping the airways open, thereby improving breathing efficiency.
Therapeutic Uses:
Long-term management of bronchial asthma
Maintenance therapy in moderate to severe COPD
Prevention of asthma attacks and reduction in COPD exacerbations
Mechanism of Action:
Formoterol is a long-acting beta-2 agonist (LABA) that relaxes the smooth muscles in the airways, resulting in sustained bronchodilation and easier airflow.
Fluticasone Propionate is a corticosteroid that reduces inflammation, swelling, and mucus production in the lungs, helping to control chronic respiratory symptoms.
Dosage Form:
Metered-Dose Inhaler (MDI) or Dry Powder Inhaler (DPI), depending on formulation
Strength:
Formoterol 6 mcg
Fluticasone Propionate 250 mcg per actuation
Prescription Status:
Prescription-only medication
Note:
This medication is intended for regular, long-term use and is not suitable for the immediate relief of acute bronchospasm. Patients should be advised to use a fast-acting reliever inhaler when needed. Rinse the mouth after each use to reduce the risk of oral thrush. Use under medical supervision for optimal effectiveness.
Would you like this description adapted for use in product literature, digital listings, or regulatory documents?
